Monday, 16 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleMotley Fool

Why Iovance Biotherapeutics Stock Was on Fire Today

View original at fool.com
Motley Fool - Stock Analysis Title: Why Iovance Biotherapeutics Stock Was on Fire Today Date: 2026-09-24 23:57 Source: https://www.fool.com/investing/2026/09/24/why-iovance-biotherapeutics-stock-was-on-fire-toda/?source=iedfolrf0000001 <p>A new, bullish analyst take on <strong>Iovance Biotherapeutics</strong> <span cla…
Opening lines of the source · Motley Fool · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rated Iovance Biotherapeutics equity a buy with a price target of $15 per share upon resuming coverage of the stock.

    60% confidence

Cited in these Via News reports